Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
| dc.authorid | Chan, Stephen Lam/0000-0001-8998-5480 | |
| dc.authorid | Rimassa, Lorenza/0000-0001-9957-3615 | |
| dc.authorid | Dadduzio, Vincenzo/0000-0002-3193-6632 | |
| dc.authorid | Cicin, Irfan/0000-0002-7584-3868 | |
| dc.authorwosid | Chan, Stephen Lam/F-9149-2011 | |
| dc.authorwosid | Rimassa, Lorenza/N-4884-2016 | |
| dc.authorwosid | Dadduzio, Vincenzo/AAA-6562-2019 | |
| dc.authorwosid | Park, Jun Yong/H-7127-2019 | |
| dc.authorwosid | Cicin, Irfan/AAQ-5575-2020 | |
| dc.contributor.author | Abou-Alfa, Ghassan K. | |
| dc.contributor.author | Meyer, Tim | |
| dc.contributor.author | Cheng, Ann-Lii | |
| dc.contributor.author | El-Khoueiry, Anthony B. | |
| dc.contributor.author | Rimassa, Lorenza | |
| dc.contributor.author | Ryoo, Baek-Yeol | |
| dc.contributor.author | Cicin, Irfan | |
| dc.date.accessioned | 2024-06-12T11:22:27Z | |
| dc.date.available | 2024-06-12T11:22:27Z | |
| dc.date.issued | 2018 | |
| dc.department | Trakya Üniversitesi | en_US |
| dc.description | Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CA | en_US |
| dc.description.abstract | [Abstract Not Available] | en_US |
| dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
| dc.identifier.doi | 10.1200/JCO.2018.36.4_suppl.207 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.issn | 1527-7755 | |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.uri | https://doi.org/10.1200/JCO.2018.36.4_suppl.207 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14551/25936 | |
| dc.identifier.volume | 36 | en_US |
| dc.identifier.wos | WOS:000436174100199 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott Williams & Wilkins | en_US |
| dc.relation.ispartof | Journal Of Clinical Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | [No Keywords] | en_US |
| dc.title | Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. | en_US |
| dc.type | Conference Object | en_US |
